Tillotts Pharma AG

Company snapshot

Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with close to 400 employees in Switzerland and abroad. Tillotts is dedicated to the development, acquisition and commercialization of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products for the treatment of IBD and Clostridioides difficile infecti

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Tillotts Pharma AG. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Tillotts Pharma AG.

1. Jun 8, 2026 Clinical update

   Asacol® — Phase 3

View all clinical trial activity →

• What is Tillotts Pharma AG?

  Tillotts Pharma AG is a pharma organization headquartered in CN. Primary therapeutic focus areas include Active Ulcerative Colitis. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and U

• Is Tillotts Pharma AG publicly traded?

  Tillotts Pharma AG appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Tillotts Pharma AG develop or market?

  We link 2 drug profile(s) where Tillotts Pharma AG is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/tillotts-pharma-gmbh#company-drugs.

• What are the latest developments for Tillotts Pharma AG?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Tillotts Pharma AG focus on?

  Tillotts Pharma AG focuses on Active Ulcerative Colitis based on our analysis of their pipeline programs and drug development activities.